Article and Video CATEGORIES
Many of you already participating on the lung cancer section of the GRACE site have seen the first few responses by Dr. Aggarwal, though they have preceded my proper introduction of her. Apologies -- we had talked a few months ago about having her start sometime around now, though I hadn't anticipated her laudable enthusiasm and courage to jump right in. So let me now provide a little background.
Dr. Charu Aggarwal is an Assistant Professor in the Hematology/Oncology Division at the University of Pennsylvania, where she has a particular focus on lung cancer. She started her medical training at the Lady Hardinge Medical College in New Delhi, then came to the US and did a Master’s in Public Health at the University of Alabama, Birmingham. She then did her internship and residency training in internal medicine at the State University of New York, Buffalo before moving to Philadelphia to do her medical oncology fellowship training at the Fox Chase Cancer Center. Last year she moved to the University of Pennsylvania to join their faculty.
Our friend Dr. Weiss here has known Dr. Aggarwal from his time in Philadelphia, as he had trained at the University of Pennsylvania and knew Dr. Aggarwal from the cancer scene in Philadelphia (I guess if you consider there to be such a thing). He had recommended here, and I've had the chance to spend some time talking with and trying to recruit her to work with us. Her background includes an impressive collection of awards for academic achievements, her research efforts, and bedside manner -- I think this is a great combination that I hope will lead to her becoming a recurring, always welcomed addition to the GRACE faculty.
Please feel free to offer comments and raise questions in our
discussion forums.
Forum Discussions
Hi elysianfields and welcome to Grace. I'm sorry to hear about your father's progression.
Unfortunately, lepto remains a difficult area to treat. Recently FDA approved the combo Lazertinib and Amivantamab...
Hello Janine, thank you for your reply.
Do you happen to know whether it's common practice or if it's worth taking lazertinib without amivantamab? From all the articles I've come across...
Hi elysianfields,
That's not a question we can answer. It depends on the individual's health. I've linked the study comparing intravenous vs. IV infusions of the doublet lazertinib and amivantamab...
Recent Comments
That's…